Vaccination with cytokine-transduced tumor cells represents a potentially important approach to the treatment of central nervous system tumors. We have recently demonstrated the therapeutic efficacy of tumor cell vaccines expressing the murine interleukin 4 (IL-4) and the herpes simplex virus-thymidine kinase in a rat brain tumor model in which nonirradiated vaccine cells can be eliminated by the subsequent administration of ganciclovir. In this report, we demonstrate the construction and characterization of a retroviral vector that encodes human IL-4, neomycin phosphotransferase, and herpes simplex virus-thymidine kinase genes for use in human clinical trials. An MFG-based retroviral vector was used to generate the recombinant retrovirus, TFG-hIL4-Neo-Tk, in which a long terminal repeat-driven polycistronic transcript encodes three cDNAs that are linked and coexpressed using two intervening internal ribosome entry site fragments from the encephalomyocarditis virus. The amphotropic retroviral vector TFG-hIL4-Neo-Tk was then used to infect human primary glioma cultures and skin-derived fibroblasts. After infection and G418 selection, cells produced 89 -131 ng/10 6 cells/48 hours of human IL-4, which was determined to be biologically active. Transduced glioma cells were highly sensitive to the cytotoxic effect of ganciclovir. These data demonstrate the suitability of the TFG-hIL4-Neo-Tk vector for therapeutic studies of cytokine-transduced autologous tumor vaccination in patients with malignant gliomas. Cancer Gene Therapy (2000) 7, 486 -494
M alignant gliomas are highly lethal cancers with invasive growth characteristics. Despite advances in multimodality treatments of these tumors, including microsurgery, chemotherapy, and radiotherapy, the median survival time of patients with glioblastoma continues to be Ͻ1 year. 1 The view of the central nervous system (CNS) as an immunologically privileged site has been supported by observations that adjuvant immunotherapies, which are effective in preventing the systemic recurrence of melanoma, have failed to prevent relapses in the CNS. 2 However, the immunological privilege of the brain is not absolute. Cellular immune responses consisting of infiltrating T lymphocytes in human brain tumors have been observed. 3 Furthermore, recent reports from our laboratory and others have shown that peripheral immunization with cytokine-gene modified tumor cell vaccines can generate effective anti-CNS tumor immune responses. 4 -6 In particular, we have demonstrated, using the rat 9L gliosarcoma model, that interleukin-4 (IL-4)-transduced tumor administration induces potent protective and therapeutic immune responses against CNS tumors. 7 The efficacy of locally produced IL-4 from genetically engineered tumor cells to induce potent antitumoral immunity has also been demonstrated by other investigators in protective 8, 9 and therapeutic 10, 11 non-CNS animal models. IL-4, in combination with granulocyte-macrophage colony-stimulating factor, also promotes the acquisition of a dendritic cell (DC) phenotype and function in mouse bone marrow 12 and human cord blood CD34 ϩ cell 13 cultures. Thus, IL-4 is now widely used in clinical trials of DC-based cancer therapy. 14 -16 Interestingly, it has been reported that IL-4-transduced cancer cells increased the influx of DCs to the tumor site relative to other cytokines, 17 suggesting that local IL-4 expression at the vaccination site may enhance tumor antigen presentation through effective recruitment of DCs. In our studies, we have made use of a retroviral vector (MFG) as a vehicle to introduce the IL-4 gene into the tumor. 18 To enhance the safety of vaccine administration for human clinical trials, we introduced the herpes simplex virusthymidine kinase (HSV-TK) gene into a retroviral vector encoding IL-4 and neomycin phosphotransferase (neo R ) genes using internal ribosome entry sites (IRES). We used IRES sequences to construct a retroviral vector, TFG-hIL4-Neo-Tk, which encodes the human IL-4 (hIL-4), neo R and the HSV-TK genes. The IRES sequence was originally obtained from the 5Ј nontranslated region of the encephalomyocarditis virus, and allows cap-independent translation. A single polycistronic transcript from two or more separate genes can thus be transcribed downstream of the retroviral long terminal repeat, and each gene can be translated. 7,19 -21 Transduction with the HSV-TK gene renders mitotic cells sensitive to subsequent treatment with the antiviral drug ganciclovir (GCV), because HSV-TK specifically phosphorylates GCV to a toxic intermediate metabolite that inhibits DNA synthesis. 22 Infection of glioma cells with HSV-TK-expressing retroviruses followed by treatment with GCV has been used to produce tumor regression in preclinical models 23, 24 and has been demonstrated to be applicable for use in human clinical trials. 25 Furthermore, it has been reported that antitumoral immunity can be induced after the HSV-TKmediated killing of experimental tumors in vivo. 26, 27 By incorporating the HSV-TK gene into glioma vaccines and subsequently treating vaccinated patients with GCV, we intend both to minimize the potential for local tumor growth and also to enhance the likelihood of inducing an antitumoral immune response at the vaccine site by releasing tumor antigens possibly accompanied by upregulation of heat shock proteins. 27 We have demonstrated the efficacy and feasibility of this approach using a rat 9L model. 7 In this study, we examined the applicability of the TFG-hIL4-Neo-Tk vector in the ex vivo transduction of human glioma cells and fibroblasts to generate cancer vaccines. In this regard, several technical aspects of this procedure are critical to ensure the success of this approach. First, primary glioma tissues harvested at the time of surgery need to be cultured in vitro. Second, cultured glioma cells must be transfected with retroviral vectors and selected transfectants need to be expanded. In addition, the products of all genes coded in the vector must be efficiently expressed. In this report, we demonstrate that cultured primary glioma cells were successfully transduced with a retroviral vector (TFG-hIL4-Neo-Tk), expanded after the selection with G418, and expressed biologically active transgenes. These findings support the feasibility of clinical trials using this approach.
MATERIALS AND METHODS

Tumor cells and fibroblasts
Surgical specimens were obtained from eight patients with a histological diagnosis of malignant glioma. Tumor tissues were transferred to sterile phosphate-buffered saline, cut into 2-mm pieces with scissors, enzymatically digested in Dulbecco's modified Eagle's medium (DMEM) containing 0.25% collagenase type I (Sigma, St. Louis, Mo), and slowly stirred for 1 hour at 37°C. The resulting cell populations were passed through a 70-m mesh cell strainer (Sigma). The collected cells were washed three times in Hanks' balanced salt solution before plating onto dishes. This process yielded ϳ1 ϫ 10 6 viable tumor cells per 1.0 g of tumor tissue. Cultures were maintained in DMEM supplemented with 10% fetal bovine sera, 100 U/mL penicillin G, and 100 U/mL streptomycin sulfate, at 37°C with 5% CO 2 . Cells were fed with fresh medium every 3-4 days. When the cultures reached 80% confluency, they were treated with trypsin, counted, and subcultured at ratios ranging from 1:3 to 1:10. The culture of human fibroblasts was performed as described previously. 28 Briefly, pieces of dermal tissue were digested with 1% collagenase (Sigma) and incubated in a complete fibroblast culture medium consisting of fibroblast basal medium (Clonetics, San Diego, Calif) supplemented with 10% human AB sera (NABI, Miami, Fla), 5 g/mL human recombinant basic fibroblast growth factor (Clonetics), 50 g/mL gentamicin, and 250 ng/mL amphotericin B. The 9L rat gliosarcoma cells were maintained in minimum essential medium supplemented with 10% fetal bovine serum, 100 U/mL penicillin G, and 100 U/mL streptomycin sulfate.
Recombinant retroviral vectors and infection
cDNAs of hIL-4, neo R , and HSV-TK were subcloned into MFG 29 (Fig 1) . The hIL-4 cDNA fragment from pBluescript was made by polymerase chain reaction (PCR), generating a NcoI site at the first ATG and a BamHI site directly 3Ј to the stop codon. This NcoI-BamHI fragment was inserted into an MFG backbone to generate MFG-hIL4. To construct an IRES-Neo cassette, the pCITE plasmid (Novagen, Madison, Wis) containing the IRES sequence from the encephalomyocarditis virus was digested downstream from the IRES sequence with BsxXI and StuI; next, a BamHI linker was ligated on the StuI site. The neo R fragment, made by PCR from the plasmid pTKneo (Strategene, Cambridge, Mass) using primers to create a 5Ј BstXI site at the ATG and a BamHI site 3Ј to the stop codon, was then cloned into the pCITE plasmid at the OKADA, ATTANUCCI, TAHARA, ET AL: AN IL-4 PLUS HSV-TK RETROVIRAL VECTOR FOR GLIOMA VACCINE BsxXI and BamHI sites. The EcoRI-BamHI fragment containing IRES-Neo was ligated with a BamHI linker on the EcoRI site to generate a BamHI-BamHI fragment, which was inserted into the BamHI site of MFG-hIL-4 to construct DFG-hIL4-Neo. The IRES-Tk cassette was similarly constructed. TFGhIL4-Neo-Tk was constructed by partial digestion with BamHI and insertion of the IRES-Tk cassette. As shown in Figure 1 , the TFG vector is capable of coordinately expressing three independent genes from a single transcript.
Generation of producer lines
The CRIP packaging line 18 and NIH-3T3 fibroblast line were maintained in DMEM supplemented with 10% calf sera, 100 U/mL penicillin G, and 100 U/mL streptomycin sulfate. The TFG-hIL4-Neo-Tk vector plasmid was transfected into the CRIP packaging line using the calcium phosphate precipitation method. After G418 selection (0.75 mg/mL, Life Technologies, Gaithersburg, Md), the supernatants from resulting clones were isolated and expanded. Aliquots of supernatant from each clone were screened for their ability to infect NIH-3T3 cells. To estimate the titer of each producer clone, 10-fold serial dilutions of the supernatant of each clone were used to infect 5 ϫ 10 5 NIH-3T3 cells. After 48 hours, the cells were split 1:20 and cultured in the presence of 0.75 mg/mL G418. After 12 days, the number of G418-resistant colonies was counted; the clone with the highest titer consistently produced 2-5 ϫ 10 4 colony-forming units/mL. This producer clone was designated as CRIP/TFG-hIL4-Neo-Tk and was used in all subsequent experiments.
Transduction and selection of transfected cells
The CRIP/TFG-hIL4-Neo-Tk cells were grown to confluency in T-75 flasks (Falcon, Becton Dickinson, Lincoln Park, NJ), and the medium was replaced with 5 mL of complete media (DMEM ϩ 10% calf serum). The viral fluid was harvested 48 hours later and filtered (0.45 m). Early passage cultured human glioma cells, fibroblasts, or 9L rat gliosarcoma cells in the log phase of growth were transduced with the retroviral vector TFG-hIL4-Neo-Tk. Aliquots of 2 ϫ 10 5 target cells were placed in T-25 flasks (Falcon, Becton Dickinson) 1 or 2 days before transduction. The cells were incubated with 2 mL of filtered vector supernatant in the presence of 8 g/mL of polybrene for 16 hours at 37°C in 5% CO 2 . In some cases, human glioma cells were centrifuged during the transduction using a Sorvall 6000D tabletop centrifuge (Sorvall, Newton, Conn) at 834 ϫ g for 2 hours at 32°C. 30 Centrifuged cells were then incubated for an additional 14 hours with supernatant at 37°C with 5% CO 2 . Viral supernatant was removed and replaced with fresh complete media. G418 (0.6 mg/mL) was added at 2 days posttransduction, and transfected cells were selected continuously for 2 weeks. Colonies were collected and expanded for the following experiments.
hIL-4 enzyme-linked immunosorbent assay (ELISA)
The hIL-4 production of the transfected tumor cells was measured by ELISA using antibodies (Abs) purchased from PharMingen (San Diego, Calif) with a sensitivity ranging from 15 to 2000 pg/mL. IL-4 levels were expressed as nanograms/10 6 cells/48 hours.
Phytohemogglutinin (PHA) blast proliferation assay
Heparinized peripheral blood was obtained from a healthy donor. Peripheral blood mononuclear cells were separated on a Ficoll-Hypaque density gradient (Lymphoprep, Nyegaard, Oslo, Norway) and incubated for 1 hour in plastic flasks to partially deplete adherent monocytes. A total of 1 ϫ 10 6 peripheral blood mononuclear cells/mL were incubated for 3 days with 5 ng/mL of PHA (Difco, Detroit, Mich). The ability of the hIL-4 produced by TFG-hIL4-Neo-Tk-transfected 9L rat gliosarcoma cells to induce the proliferation of PHA blasts was analyzed in a 48-hour [ 3 H]thymidine incorporation assay. Because IL-4 is species-specific, we used rat 9L cells rather than human glioma cells to eliminate the possibility of activating PHA by endogenous hIL-4 production. Also, it was thought unlikely that differences in posttranslational modification between rat and human glioma cells would be critically different. A total of 5 ϫ 10 4 PHA blasts/well were incubated in AIM V plus 10% AB sera at a density of 5 ϫ 
Immunocytochemistry
The glial nature of the cultured cells was confirmed by immunocytochemical staining for glial fibrillary acidic protein (GFAP). Cells inoculated and cultured overnight on chamber slides were washed once in phosphate-buffered saline and fixed in acetic acid-ethanol for 15 minutes at room temperature. Anti-GFAP polyclonal rabbit Ab (Dako, Carpinteria, Calif) was used at a 1/500 dilution and the immunoreactivity was visualized using a streptavidin biotin kit (Dako) followed by diaminobenzidine detection. Cells were counter-stained with crystal violet.
RESULTS
Primary cultures of human gliomas and transfection with TFG-hIL4-Neo-Tk vector Primary glioma cell lines were established from seven of eight tumors. Cultures were designated as HG1 through HG8, including the HG6 cells that ultimately failed to grow. Variable growth rates were observed among all lines. Relatively fast-growing lines, such as HG3 and HG5, doubled every 3 to 4 days; HG1, HG2, HG4, and HG8 grew more slowly, with doubling times from 5 to 8 days. All cell lines except HG2, HG3, and HG5 stopped proliferating after five to six passages. Cultures of HG2, HG3, and HG5 were transduced with the retroviral vector TFG-hIL4-Neo-Tk within the first two passages. Two primary fibroblast lines, F1 and F2, as well as 9L rat glioma cells were also transduced. Transduced cells were selected with G418. The efficiency of the transfer for glioma cells is demonstrated as the numbers of G418-resistant colonies in Table 1 . Cells that had been transduced with the TFG-hIL4-Neo-Tk vector were termed HG2-hIL4-Tk, HG3-hIL4-Tk, HG5-hIL4-Tk, F1-hIL4-Tk, F2-hIL4-Tk, and 9L-hIL4-Tk, respectively.
Expression of IL-4 by ELISA and PHA blast proliferation assay hIL-4 production was determined by ELISA, and the bioactivity of the transgene-derived IL-4 was demonstrated by a PHA blast assay. As shown in Table 2 , TFG-hIL4-Neo-Tk transfectants expressed 89 -131 ng/ 10 6 cells/48 hours of hIL-4, whereas control nontransduced cells produced undetectable levels of IL-4. The biological activity of the transgene-derived IL-4 was examined in a PHA blast proliferation assay. As shown in Figure 2 , the supernatant from 9L-hIL4-Tk induced the proliferation of PHA blasts in a dose-dependent manner, indicating that the transgene-derived IL-4 was biologically active, whereas 9L-Neo supernatants induced no proliferation (Fig 2A) . PHA blast proliferation was completely blocked by the addition of neutralizing anti-IL4 Ab, but not by isotype control Ab (Fig 2B) , indicating that the proliferation was IL-4-specific.
Transfected glioma cells are sensitive to the cytotoxic effect of GCV To evaluate the sensitivity of HG2-hIL4-Tk and HG5-hIL4-Tk to GCV, aliquots of cells were incubated with graded concentrations of GCV for 7 days or 14 days. Figure 3 shows the cell survival fraction of GCV-treated HG2-hIL4-Tk (Fig 3A) and HG5-hIL4-Tk (Fig 3B) cells, which corresponded to the percentage of viable cells in cultures grown in the presence of GCV and to viable cells in preparations grown without GCV, respectively. The survival fraction of both HG2-hIL4-Tk cells and HG5-hIL4-Tk cells was reduced with increasing concentrations of GCV and longer culture periods. In the HG2-hIL4-Tk cell line, 51% and 0.7% of the cells survived on days 7 and 14 after the addition of 10 g/mL GCV, respectively. HG5-hIL4-Tk cells appeared to be even more sensitive to the cytotoxic effects of GCV, with only 0.3% and 0.1% remaining viable after treatment with 10 g/mL GCV for 7 and 14 days, respectively. High-dose GCV treatment alone had a mild inhibitory effect on the growth of control cells lacking the transduced HSV-TK gene.
Both parental and transduced glioma cells are GFAP-positive
To verify that cultured and transfected cells derived from surgically resected gliomas are tumor cells of glial origin and not other contaminating cells, such as fibroblasts or endothelial cells, we performed immunocytochemical staining for GFAP, a specific marker of glial cell lineage. Figure 4 shows cells stained with anti-GFAP Ab. Cytosolic staining with anti-GFAP Ab was observed in HG2-hIL4-Tk cells (Fig 4A) and was weakly positive in HG5-hIL4-Tk cells (Fig 4B) , whereas the control fibroblast line F1 was negative for GFAP (Fig 4C) , confirming the glial identity of the tumor-derived cell cultures.
DISCUSSION
Active immunotherapy is a promising but unproven treatment for malignant gliomas. Our preclinical study of peripheral immunization with IL-4 plus HSV-TKtransduced tumor cells, in which potent and specific immune responses against intracranial tumors were demonstrated, 7 provided a rationale for the implementation of phase I clinical trials of IL-4-modified tumor vaccines in patients with recurrent high-grade gliomas. It has been reported recently that direct retroviral delivery of IL-4 at intracranial tumor sites also induces tumor rejection and potent immunity in rat glioma models. 31 However, we have observed that IL-4 gene-transduced peripheral vaccine approaches are more effective than intracranial vector delivery for inducing immunity the against 9L intracranial rat glioma model (our manuscript in preparation) and have therefore favored a peripheral vaccination strategy for clinical application.
The preparation of clinically useful tumor vaccines will require the ability to generate cultures of tumor specimens from each patient in a timely fashion and to transduce these cultures with an expression vector that allows for adequate local secretion of the cytokine. The present study provides data supporting the feasibility of generating glioma vaccines ex vivo by showing that primary glioma cells can be expanded after transfection with the retroviral vector TFG-hIL4-Neo-Tk, and that transfected cells express biologically active IL-4 and are rendered sensitive to the cytotoxic effect of GCV. We were successful in establishing and expanding primary glioma cell cultures in seven of eight tumors examined. However, expansion of these cell cultures was variable. In the case of HG5, for example, 2 ϫ 10 4 -fold expansion was achieved after 10 passages. However, we failed to sufficiently expand cells in four other cases, indicating some technical limitations of this approach.
A retroviral vector system can provide stable and long-term expression of the transgene in the infected cells without the expression of viral genes that would cause a nonspecific immune response to the infected cells. The retroviral vector TFG-hIL4-Neo-Tk efficiently infected some human glioma cells. In rapidly proliferating cells (HG5), after infection and selection, 3-fold expansion of transfectants was achieved by 21 days postinfection. This cell line has subsequently been dividing every 3-4 days, a rate sufficient to generate vaccine cells in a clinically useful time. As retroviral vectormediated transduction is dependent upon the active proliferation of the target cells, 32 slow-growing lines predictably are difficult to infect. However, difficulty in transduction was also seen in one of the rapidly proliferating cell lines, HG3, suggesting that there may be other factors that determine the susceptibility of the target cells. Centrifugation increased transduction effi- HG5-IL4-Tk (B) ). Aliquots of cells were incubated with various concentrations of GCV for 7 days or 14 days. The number of viable cells was counted, and the percentage of survival was determined by comparison with that of the same transfectants cultured without GCV. F, HG2-hIL4-Tk (A) or HG5-hIL4-Tk (B) cells cultured with GCV for 7 days; OE, HG2-hIL4-Tk (A) or HG5-hIL4-Tk (B) cells cultured with GCV for 14 days; E, control nontransduced cells (HG2 (A) or HG5 (B) ) cultured with GCV for 7 days; ‚, control nontransduced cells (HG2 (A) or HG5 (B) ) cultured with GCV for 14 days. After transfection and selection, cells were confirmed to express biologically active IL-4 ( Table 2, Fig 2) and to be sensitive to the toxic effect of GCV (Fig 3) . The effect of autocrine IL-4 on the growth and vascular cell adhesion molecule-1 expression of glioma cell lines was examined (data not shown). Although some lines, such as HG5, were found to be positive for IL-4 receptor by reverse transcriptase-PCR level, none of the cell lines examined has been influenced in vitro in terms of either proliferation or vascular cell adhesion molecule-1 expression by exogenous recombinant IL-4 (0.2-20 ng/ mL). Although a recent study has demonstrated that IL-4 is capable of inducing apoptotic cell death in some human breast cancer cell lines, 33 this does not appear to be a concern in glioma cells. Of course, if there are glioma lines that undergo apoptosis after exposure to IL-4; we may encounter difficulty in transducing and growing those cell lines.
In our CGV sensitivity assay, HG2-hIL4-Tk cells were less sensitive than HG5-hIL4-Tk, presumably because HG2 cells proliferate less rapidly than HG5. In an animal model using a live glioma cell vaccine, tumor cells expressing murine IL-4 and HSV-TK grew at the site of immunization for 10 days, after which there was regression and elimination of subcutaneous tumors. 7 We anticipate a similar response in patients if they are able to generate an effective immune response to the tumor. To reduce the possibility of local tumor growth, all patients will be treated intravenously with 5 mg/kg GCV after each set of vaccinations, which should yield peak serum concentrations of 9.5-11.6 g/mL. Our in vitro GCV sensitivity assay showed that both HG2-hIL4-Tk and HG5-hIL4-Tk can be eliminated almost completely by incubation with 10 g/mL GCV for 14 days, indicating that mitotically active vaccine cells should be eliminated in vivo. However, because of the potential for variation between transduced cell lines in their sensitivity to GCV, we plan to test the sensitivity of each vaccine to GCV before using it clinically. Also, the vaccine might be tested for irradiation sensitivity in the event that irradiation is necessary. To improve the expression of the transgenes, further modification of the vector construct, such as incorporation of leader sequences, 34 may be considered in the future.
Although efficient retroviral gene transfer has been demonstrated in human glioma cells using MFG-based vectors encoding cDNAs for cytokines, 35 their system is based on the use of an irradiated glioma cell vaccine, which eliminates the necessity of selecting transduced cells. Because we have found that nonirradiated cells are more effective at inducing antitumoral immune responses after vaccination, 7 we have constructed a vector encoding cDNAs for the neo R selection marker, HSV-TK, and IL-4, which allows us to use selected transfected cells for the nonirradiated cell vaccination. It has been demonstrated recently that the killing of tumor cells by the HSV-TK gene and GCV induces heat shock protein-70 expression; this expression enhances the immunogenicity of tumor cells, 27 suggesting our strategy of a combination of IL-4 and HSV-TK may enhance tumor immunogenicity in vivo.
An important consideration for developing transduced cell lines involves the confirmation that the vast majority of transduced cells are of glial origin. GFAP staining of transduced cells verified a glial lineage of vaccine cells. Although the cultures in low passages could contain a mixture of tumor cells and other components from the brain, non-neoplastic contaminants gradually disappear after several passages. Because only actively proliferating cells can be transfected with retroviral vectors, most live cells are presumed to be glioma cells after selection with G418.
The results shown here indicate that we may encounter some difficulty in transducing glioma cells in our projected clinical trials. Therefore, alternative strategies are needed to attain high-level gene expression at the vaccination site if autologous tumor cells prove difficult to transfect and select in a timely way. We have considered a variety of approaches for this situation, including the use of cytokine-transfected allogeneic tumors or adenoviral vectors. Unfortunately, these create additional problems, including the fact that a common tumor antigen has yet to be identified in glioma cells, which will limit the utility of allogeneic vaccines, and that the allogeneic and adenoviral antigens themselves may cause deviation of the immune response. For patients whose glioma cells prove difficult to transfect, we will use IL-4-transduced, autologous fibroblasts admixed with irradiated autologous tumor cells. It has been shown previously that immunization with IL-4- 36 or IL-12-37 transduced fibroblasts admixed with irradiated tumor cells induces potent antitumoral immunity. Expression of the cytokines from autologous fibroblasts at the vaccine site and the safety of these protocols have been demonstrated in clinical trials. 38, 39 Although vaccination with whole tumor cells or tumor cell extracts eliminates the requirement to identify tumor-specific or tumor-associated antigens, some investigators have raised concerns that application of this approach for CNS tumors could result in the development of potentially deleterious autoimmune encephalitis. This toxicity, which is seen in models of experimental allergic encephalomyelitis after the systemic immunization of host animals with brain-specific proteins 40 or after the adoptive transfer of T lymphocytes recognizing a brain-associated protein, 41 has been described in other studies of non-human primates and guinea pigs after cross-species immunization with human glioblastoma multiforme tissue. 42 However, allergic encephalitis has not been observed in other preclinical models or human clinical trials of brain tumor vaccines. In four welldocumented trials of autologous or allogeneic glioma vaccines involving a total of 76 patients, including one case of IL-2 tumor vaccine, 43 only one case of mild, transient encephalopathy has been reported after vaccination. 44 -46 Although these results suggest that the risk of autoimmune encephalitis should be quite low in our planned phase I study of IL-4 glioma vaccine, this will clearly constitute a major safety-monitoring endpoint of the protocol. Induction of an immune response will also be evaluated by serial biopsy of the vaccine sites. Therapeutic efficacy will be evaluated by radiographic monitoring of the tumor size. The study will also determine the optimum cell dosage and schedule of vaccination for the subsequent phase II trials. The Food and Drug Administration has approved our application for evaluating the TFG-hIL4-Neo-Tk vector, used in nonirradiated human glioma cell vaccines, as an investigational new drug. Safety testing for the vector master cell bank and the vector supernatant, including analyses for sterility and the absence of mycoplasmas, endotoxin, and replication-competent retroviruses, has been completed.
